A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : UMEC / umeclidinium

[Related PubMed/MEDLINE]
Total Number of Papers: 52
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   UMEC  (>> Co-occurring Abbreviation)
Long Form:   umeclidinium
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2022 A single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol for the treatment of COPD. FF, SITT
2022 Is single-inhaler triple therapy for COPD cost-effective in the UK? The IMPACT trial. COPD, FF, ICERs, LYs, QALYs
2021 Comparison of COPD health care utilization and associated costs across patients treated with LAMA+LABA fixed-dose therapies. COPD, ED, ERS, FDC, HCRU, LABA, LAMA, OLO, TIO
2021 Effect of Age on Efficacy and Safety of Fluticasone Furoate/Vilanterol (FF/VI), Umeclidinium (UMEC), and UMEC + FF/VI in Patients with Chronic Obstructive Pulmonary Disease: Analyses of Five Randomized Clinical Trials. COPD, DPI, FEV1, FF, FF/VI
2021 INTREPID: single- versus multiple-inhaler triple therapy for COPD in usual clinical practice. CAT, FEV1, FF, MITT
2021 Population Pharmacokinetic Modeling of Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol in Patients with Asthma, Using Data from a Phase IIIA Study (CAPTAIN). BQL, FF, ICS, LABA, PK
2020 A phase IIb, randomised, parallel-group study: the efficacy, safety and tolerability of once-daily umeclidinium in patients with asthma receiving inhaled corticosteroids. FEV1, FF
2020 Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD: A Post Hoc Analysis of the Informing the Pathway of COPD Treatment Trial. CFB, FF, IMPACT, SGRQ
2020 Efficacy and Safety of Once-Daily Inhaled Umeclidinium in Asian Patients with COPD: Results from a Randomized, Placebo-Controlled Study. AEs, CFB, CI, COPD, FEV1, LS, TDI
10  2020 Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACT. FF, ITT, SITT
11  2020 Single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the China cohort in the IMPACT trial. CI, COPD, FEV1, FF
12  2020 Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study. BDI, CAT, COPD, FF, HRQoL, SGRQ, TDI
13  2020 The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial. FF, ICS
14  2019 Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial. CI, COPD, FF, ICER, LYs, QALYs
15  2019 Effect of triple therapy in patients with asthma-COPD overlap
. COPD, FF/VI, Fres
16  2019 Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease. COPD, FF
17  2018 Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting beta2-Agonist Therapy: An Integrated Post Hoc Analysis. AEs, CID, COPD, FEV1, GOLD, ICS, ITT, LABA, SGRQ
18  2018 Relationship between exercise endurance and static hyperinflation in a post hoc analysis of two clinical trials in patients with COPD. COPD, EET, IC, RV, TLC
19  2017 A phase 2a randomized controlled study to evaluate the pharmacokinetic, safety, tolerability and clinical effect of topically applied Umeclidinium in subjects with primary axillary hyperhidrosis. HDSS, LAMA
20  2017 Intracellular interactions of umeclidinium and vilanterol in human airway smooth muscle. ASMCs, beta2R, cAMP, MCh, RGS2
21  2017 The effect of umeclidinium on lung function and symptoms in patients with fixed airflow obstruction and reversibility to salbutamol: A randomised, 3-phase study. COPD, FEV1, FF, PEF
22  2017 Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study. AEs, CAT, CI, FEV1, LS, mMRC, SGRQ, TDI, TIO
23  2016 A Novel Method for Studying the Pharmacokinetics of [(14) C]Umeclidinium After Application to the Axilla or Palm of Healthy Male Subjects. COPD, OA, OP, UA
24  2016 A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol. COPD, FF, GOLD, ICS, IMPACT, LABA, LAMA
25  2016 A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 mug compared with tiotropium 18 mug in patients with COPD. CI, FEV1, PP, TIO
26  2016 A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 mug on health-related quality of life in patients with COPD. CI, COPD, PBO, SGRQ
27  2016 Concentration-QT analysis of the randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects. PI, QTcF
28  2016 Population Pharmacokinetics Modeling of Inhaled Umeclidinium for Adult Patients with Asthma. AUC
29  2016 The effect of umeclidinium added to inhaled corticosteroid/long-acting beta2-agonist in patients with symptomatic COPD: a randomised, double-blind, parallel-group study. AEs, CAT, FEV1, ICS, LABA, LAMA, PBO, TDI, WM
30  2015 A randomized, crossover study to investigate the pharmacokinetics and safety of inhaled fluticasone furoate and umeclidinium, administered separately and in combination via dry powder inhaler in healthy adult volunteers. FF, PK
31  2015 A Systematic Review of the Efficacy and Safety of a Fixed-Dose Combination of Umeclidinium and Vilanterol for the Treatment of COPD. AEs, LABAs, LAMAs, NNTB, SAEs, SCVEs, Vil
32  2015 Dose-response modelling of umeclidinium and fluticasone furoate/umeclidinium in asthma. FF, ICS
33  2015 Efficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled study. CI, FEV1, TDI, WM
34  2015 Efficacy and Safety of Umeclidinium Added to Fluticasone Propionate/Salmeterol in Patients with COPD: Results of Two Randomized, Double-Blind Studies. CAT, COPD, FEV1, PBO, SGRQ, WM
35  2015 Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. CI, COPD, FEV1, FP/SAL, LABA, LAMA, QoL, WM
36  2015 In Vitro Dosing Performance of the ELLIPTA Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™). COPD, DD, ETD, FF, FPD
37  2015 Is Blood Eosinophil Count a Predictor of Response to Bronchodilators in Chronic Obstructive Pulmonary Disease? Results from Post Hoc Subgroup Analyses. AE, COPD, EOS, ICSs, SGRQ, TDI
38  2015 Pharmacokinetics and tolerability of inhaled umeclidinium and vilanterol alone and in combination in healthy Chinese subjects: a randomized, open-label, crossover trial. AE, PK, Tmax, UMEC/VI
39  2015 Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial. COPD, FEV1, FP/SAL, QoL, WM
40  2014 A randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects. CI, QTcF
41  2014 A randomized, three-period crossover study of umeclidinium as monotherapy in adult patients with asthma. ICS, OD
42  2014 Differential pharmacology and clinical utility of emerging combination treatments in the management of COPD--role of umeclidinium/vilanterol. COPD
43  2014 Dose response of umeclidinium administered once or twice daily in patients with COPD: a pooled analysis of two randomized, double-blind, placebo-controlled studies. COPD
44  2014 Effects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double-blind clinical trials. COPD, EET, FEV1
45  2014 Effects of moderate hepatic impairment on the pharmacokinetic properties and tolerability of umeclidinium and vilanterol in inhalational umeclidinium monotherapy and umeclidinium/vilanterol combination therapy: an open-label, nonrandomized study. ---
46  2014 Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. COPD, FEV1, TIO
47  2014 Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study. AEs, COPD, LABA, LAMA, SAEs
48  2014 The effect of fluticasone furoate/umeclidinium in adult patients with asthma: a randomized, dose-ranging study. FF, ICS, PEF
49  2014 Umeclidinium for treating COPD: an evaluation of pharmacologic properties, safety and clinical use. COPD, LAMA
50  2013 Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label study. COPD, CYP3A4
51  2013 The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects. ATS, COPD, EMA, ERS, FDA, FDC, GOLD, LABAs, LAMAs, NDAs
52  2012 28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial. AEs, COPD, LAMA